All In Biotech

Drug Trial Radar · NCT01101035

Cardiovascular Safety of Febuxostat and Allopurinol in Participants With Gout and Cardiovascular Comorbidities (CARES)

A Multicenter, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects With Gout and Cardiovascular Comorbidities

Last checked: Nov 20, 2026Latest source record: Jun 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 6,198 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,198

Actual

Start

Apr 23, 2010

Primary completion

May 15, 2017

Study completion Jul 18, 2017

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Apr 9, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to see whether subjects with gout who receive febuxostat or allopurinol for up to 9 years have a higher rate of serious heart and blood vessel complications (major cardiovascular events).

Conditions

  • Cardiovascular Disease

Interventions

  • FebuxostatDrug

    Febuxostat tablets

  • AllopurinolDrug

    Allopurinol tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Primary Major Adverse Cardiovascular Events (MACE) Composite (75% Interim Analysis)Time frame: Up to last dose of study drug (approximately 83 months)
  2. Percentage of Participants With Primary MACE Composite (Final Analysis)Time frame: Up to last dose of study drug (approximately 83 months)

Locations

203 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Decatur, Georgia

  • Site not named

    Dunwoody, Georgia

  • Site not named

    Marietta, Georgia

  • Site not named

    Norcross, Georgia

  • Site not named

    Roswell, Georgia

  • Site not named

    Suwanee, Georgia

  • Site not named

    Waycross, Georgia

  • Site not named

    Honolulu, Hawaii

  • Site not named

    Boise, Idaho

  • Site not named

    Coeur d'Alene, Idaho

  • Site not named

    Nampa, Idaho

  • Site not named

    Addison, Illinois

  • Site not named

    Arlington Heights, Illinois

  • Site not named

    Evanston, Illinois

  • Site not named

    Evergreen Park, Illinois

  • Site not named

    Flossmoor, Illinois

  • Site not named

    Melrose Park, Illinois

  • Site not named

    Morton, Illinois

  • Site not named

    Naperville, Illinois

  • Site not named

    Quincy, Illinois

  • Site not named

    Rockford, Illinois

  • Site not named

    Bloomington, Indiana

  • Site not named

    Brownsburg, Indiana

  • Site not named

    Lafayette, Indiana

  • Site not named

    Valparaiso, Indiana

  • Site not named

    Iowa City, Iowa

  • Site not named

    Lenexa, Kansas

  • Site not named

    Overland Park, Kansas

  • Site not named

    Topeka, Kansas

  • Site not named

    Wichita, Kansas

  • Site not named

    Elizabethtown, Kentucky

  • Site not named

    Lexington, Kentucky

  • Site not named

    Owensboro, Kentucky

  • Site not named

    Paducah, Kentucky

  • Site not named

    Mer Rouge, Louisiana

  • Site not named

    Monroe, Louisiana

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Biddeford, Maine

  • Site not named

    Rockport, Maine

  • Site not named

    Baltimore, Maryland

Showing 40 of 203 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.